VTGN
USDVistagen Therapeutics Inc. Common Stock
Real-time Price
Price Chart
Key Metrics
Market Metrics
Open
$2.400
High
$2.498
Low
$2.350
Volume
0.11M
Company Fundamentals
Market Cap
68.1M
Industry
Biotechnology
Country
United States
Trading Stats
Avg Volume
0.13M
Exchange
NCM
Currency
USD
52-Week Range
Related News
Vistagen to Report Fiscal Year 2025 Financial Results and Host Corporate Update Conference Call on June 17, 2025
Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called
Vistagen on Track to Deliver Topline Data From Fasedienol PALISADE-3 Phase 3 Trial for Acute Treatment of Social Anxiety Disorder in the Fourth Quarter of This Year
Company's PALISADE-4 Phase 3 trial now expected to read out in the first half of 2026 Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry
Vistagen to Present at the 2025 American Society of Clinical Psychopharmacology Conference
Posters Highlight New Insights into Social Anxiety Disorder and the Novel Mechanism of Action of Itruvone to Treat Major Depressive Disorder Vistagen (NASDAQ:VTGN), a clinical-stage biopharmaceutical company pioneering
Related Stocks
Stay Updated
Set price alerts, get AI analysis updates and real-time market news.